India, Aug. 11 -- Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company focused on developing and commercializing Cytisinicline for Nicotine dependence, recently reported its second-quarter 2026 financial results and provided business updates. Investors are focusing on Achieve Life's regulatory plans, commercial preparations and strengthened balance sheet.
Recent Business & Regulatory Updates
Achieve received a Complete Response Letter or CRL from the FDA in June 2026 regarding its NDA for Cytisinicline.
The company said the CRL related to outstanding current Good Manufacturing Practice or cGMP observations at its former third-party manufacturing facility and final product labeling, with no deficiencies identi...